| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | -0.29 | 0.04 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |